Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2022-06-20 Investor Presentation
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT Presenting at Gold Coast Investment Showcase 2 pages 172.0KB
Investor Presentation Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited about their upcoming presentation at the Gold Coast Investment Showcase. It includes event details, registration and livestream links, and background information about the company and its product NTCELL. There are no financial statements, detailed financial data, or regulatory filings included. The document is essentially an investor event announcement and presentation invitation rather than a report or transcript. It does not contain a transcript of the presentation, nor is it a report of financial results or management discussion. Therefore, the most appropriate classification is Investor Presentation (IP), as it focuses on informing investors about the company's presentation at an investment showcase event.
2022-06-20 English
Change of Director's Interest Notice - C Sue 2 pages 262.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report. The document length is 3234 characters, which is consistent with a detailed director's dealing notice. Therefore, the correct classification is Director's Dealing (DIRS).
2022-06-07 English
Change of Director's Interest Notice - R Willcocks 2 pages 264.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares acquired and disposed, nature of interest, and dates. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3311 characters, which is consistent with a detailed notice of director's dealings rather than a brief announcement or other report type.
2022-06-05 English
Application for quotation of securities - LCT 6 pages 27.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Application for quotation of +securities' and details the application to list new securities on the ASX (Australian Securities Exchange). It includes information about the entity, the securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. There is no financial performance data, earnings, management discussion, or audit information. The document is an announcement related to capital market activity, specifically the quotation of securities previously issued. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-06-02 English
Cleansing Notice 2 pages 177.2KB
Capital/Financing Update Classification · 95% confidence The document is a notice titled 'Cleansing notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)' dated 3 June 2022. It announces the completion of an equity raise by way of Placement, specifying the number of shares issued and the amount raised. The document references compliance with the Corporations Act and ASX Listing Rules, and provides legal assurances about disclosure and information availability. It does not contain financial statements, detailed financial analysis, or management discussion of results. The document is relatively short (5606 characters) and serves as a formal announcement related to capital raising and regulatory compliance rather than a full financial report or detailed investor presentation. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2022-06-02 English
LCT Completes Strategic A$1.285M Placement 3 pages 171.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited about completing a strategic placement to raise capital for Parkinson's disease research. It details the placement terms, the amount raised, the number of shares issued, and the purpose of the funding. There are no financial statements, quarterly or annual results, or detailed financial analysis included. The document is a capital raising announcement, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6644 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Hence, the classification is CAP with high confidence.
2022-05-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.